Orphazyme investor following muscle wasting disappointment: "Now everything has to run smoothly in 2021"

The rest of 2021 has to run perfectly for Orphazyme, according to portfolio manager, following the pharmaceutical firm's recent and disappointing study with main candidate arimoclomol for the muscle wasting disease IBM.

Photo: Orphazyme/PR

Following disappointing results for Orphazyme's main candidate arimoclomol against muscle wasting disease inclusion body myositis (IBM), which decreased the share price over 30 percent within a single trading day, the firm has two chances left which must be successful in order to set the company right again.

Advice Capital's Portfolio Manager Peter Hildebrandt tells Danish newspaper Børsen that he has kept Orphazyme in his equity portfolio in spite of the failed study.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs